{
    "clinical_study": {
        "@rank": "21681", 
        "arm_group": [
            {
                "arm_group_label": "CD07805/47 Gel 0.5%", 
                "arm_group_type": "Experimental", 
                "description": "active arm"
            }, 
            {
                "arm_group_label": "CD07805/47 Gel Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Comparator arm"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to compare the efficacy and assess the safety of CD07805/47 gel\n      0.5% applied topically once daily for 29 days versus vehicle control, in subjects with\n      moderate to severe chronic persistent vascular facial erythema"
        }, 
        "brief_title": "Phase 3 Efficacy and Safety Study of CD07805/47 Topical Gel in Subjects With Persistent Facial Erythema", 
        "completion_date": {
            "#text": "September 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Erythema", 
        "condition_browse": {
            "mesh_term": "Erythema"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Male or female, who is at least 18 years of age or older at screening visit.\n\n          -  Presence of chronic persistent vascular facial erythema for \u2265 3 months by history.\n\n          -  A Clinician's Erythema Assessment (CEA) score of \u22653 at Screening and at Pre-dose (T0)\n             on Baseline/Day 1.\n\n          -  A Patient Self Assessment (PSA) score of \u22653 at Screening and at Pre-dose (T0) on\n             Baseline/Day 1.\n\n        Exclusion Criteria:\n\n          -  More than 10 facial inflammatory lesions (papules, pustules, and nodules).\n\n          -  Presence of areas of significant scaling or crusting on the face.\n\n          -  Presence of psoriatic lesions on the face.\n\n          -  Presence of any other dermatological condition of the face that, in the opinion of\n             the Investigator, may significantly interfere with the interpretation of the clinical\n             trial results."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "84", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "June 14, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01882712", 
            "org_study_id": "RD.03.SPR.40191"
        }, 
        "intervention": [
            {
                "arm_group_label": "CD07805/47 Gel 0.5%", 
                "intervention_name": "CD07805/47 Gel 0.5%", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "CD07805/47 Gel Placebo", 
                "intervention_name": "CD07805/47 Gel Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "No", 
        "lastchanged_date": "December 19, 2013", 
        "number_of_arms": "2", 
        "overall_contact": {
            "email": "diane.rudisill@galderma.com", 
            "last_name": "Diane Rudisill", 
            "phone": "+1 6098608260"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": [
                "Brazil: National Health Surveillance Agency", 
                "Brazil: National Committee of Ethics in Research"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "September 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "1-grade improvement on both CEA and PSA at Hours 3, and 6 after Pre-dose (T0)on Day 29", 
            "measure": "Composite success on both CEA (Clinician Erythema  Assessment ) and PSA (Patient Self Assessment)", 
            "safety_issue": "No", 
            "time_frame": "Day 29"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01882712"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "1-grade improvement on both CEA and PSA at 30 minutes after pre-dose (T0) on Day 1", 
            "measure": "Composite improvement on both CEA (Clinician Erythema  Assessment ) and PSA (Patient Self Assessment)", 
            "safety_issue": "No", 
            "time_frame": "Day 1"
        }, 
        "source": "Galderma R&D", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Galderma R&D", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "March 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "December 2013"
    }
}